evolcSign inStart free
Menu

Pathios Therapeutics

Develops GPR65-targeting cancer immunotherapies for patients with solid tumors

Abingdon, United KingdomFounded 2017pathiostherapeutics.comWebsite technologies

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-10-31

About Pathios Therapeutics

Pathios Therapeutics is a drug discovery and development company developing inhibitors of GPR65, an immune-cell receptor associated with the acidic tumor microenvironment. Its lead asset, PTT-4256, is an orally bioavailable GPR65 inhibitor being advanced into clinical development.

The company focuses on oncology and immunology, with an approach intended to address immune-cell dysfunction in solid cancers. It was established in 2017 and is based in Oxford, UK; registry facts identify Abingdon as its registered HQ city. The company has raised venture funding, including a Series B round.

Product: Drug discovery and development focused on GPR65 inhibitors, including the lead asset PTT-4256.

Jobs at Pathios Therapeutics

No open positions listed right now.

Leadership

More biotech & pharma companies

  • Peptone

    Drug discovery platform designing small-molecule candidates for hard-to-treat cancers and neurodegenerative disease targets
    Mansfield, United KingdomBiotech & pharmaFounded 2018
    New on Evolc

  • Petagene

    Genomic data compression, cloud access and encryption software for genomics researchers and bioinformatics teams
    Cambridge, United KingdomBiotech & pharmaFounded 20161 open job
    New on Evolc

  • Pheno Therapeutics

    Develops GPR17-targeting neuroprotective therapeutics for patients with multiple sclerosis and other neurological disorders
    Edinburgh, United KingdomBiotech & pharmaFounded 2018
    New on Evolc

  • Phoremost

    Biotech developing oral small-molecule cancer drugs, lead programme PMC-001 for primary and metastatic brain cancers
    Cambridge, United KingdomBiotech & pharmaFounded 2014
    New on Evolc

  • Phynova Group

    Develops plant-derived health ingredients, including Reducose for blood glucose, for supplement, food and beverage makers
    Banbury, United KingdomBiotech & pharmaFounded 2004
    New on Evolc

  • Plaquetec

    Coronary artery disease endotyping and biomarker discovery for drug developers, using in-vivo plaque sampling
    Cambridge, United KingdomBiotech & pharmaFounded 2007
    New on Evolc

All biotech & pharma companies →

Website technologies

Older, unverified list. Detection dates and supporting evidence are not yet available.

  • Fastly
  • Google Analytics 4
  • Google reCAPTCHA
  • WordPress
  • jQuery